Pictet Asset Management SA raised its stake in FibroGen, Inc. (NASDAQ:FGEN – Get Rating) by 47.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 309,725 shares of the biopharmaceutical company’s stock after acquiring an additional 99,082 shares during the quarter. Pictet Asset Management SA’s holdings in FibroGen were worth $3,271,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in the stock. Primecap Management Co. CA raised its holdings in shares of FibroGen by 2.5% in the first quarter. Primecap Management Co. CA now owns 13,317,857 shares of the biopharmaceutical company’s stock worth $160,081,000 after acquiring an additional 328,734 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of FibroGen by 3.5% in the first quarter. Vanguard Group Inc. now owns 9,349,957 shares of the biopharmaceutical company’s stock worth $112,387,000 after acquiring an additional 313,769 shares during the last quarter. State Street Corp raised its holdings in shares of FibroGen by 9.3% in the first quarter. State Street Corp now owns 4,927,781 shares of the biopharmaceutical company’s stock worth $59,232,000 after acquiring an additional 420,828 shares during the last quarter. Federated Hermes Inc. increased its stake in FibroGen by 84.1% in the first quarter. Federated Hermes Inc. now owns 2,395,883 shares of the biopharmaceutical company’s stock valued at $28,799,000 after purchasing an additional 1,094,403 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in FibroGen by 333.0% in the second quarter. Assenagon Asset Management S.A. now owns 972,901 shares of the biopharmaceutical company’s stock valued at $10,274,000 after purchasing an additional 748,230 shares during the last quarter. 74.76% of the stock is owned by institutional investors and hedge funds.
FibroGen Trading Down 2.9 %
FibroGen stock opened at $14.54 on Monday. The stock has a fifty day moving average price of $14.66 and a 200 day moving average price of $12.63. FibroGen, Inc. has a 52 week low of $7.81 and a 52 week high of $18.31. The firm has a market capitalization of $1.37 billion, a P/E ratio of -3.74 and a beta of 0.86.
Analyst Ratings Changes
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
- Get a free copy of the StockNews.com research report on FibroGen (FGEN)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.